**Table S5.** Vaccine effectiveness against Alpha symptomatic disease among individuals with two doses of Vaxzevria, Comirnaty in England at 1 week, 2-9 weeks and 10+ weeks.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|   |   |   | **Dose 2** |   |   |
| Vaccine | Age group | Subgroup | week 1  | 2-9 weeks | 10+ |
| Vaxzevria  | All | All | 72.3 (66.9 to 76.9) | 81.9 (79.2 to 84.3) | 76.2 (49.8 to 88.7) |
| 65+ | All | 80.2 (69.4 to 87.2) | 87.3 (81.5 to 91.4) |
| 40-64 | All | 74.0 (64.9 to 80.7) | 80.7 (74.9 to 85.1) |
| Comirnaty | All |   | 90.3 (87.0 to 92.7) | 95.0 (93.8 to 96) | 94.8 (88.4 to 97.7) |
| 80+ | All | 78.5 (68.1 to 85.5) | 81.7 (76.2 to 85.9) | 67.1 (31.1 to 84.3) |
| 65+ | All | 85.2 (75.3 to 91.1) | 94.0 (90.3 to 96.4) |   |
| 40-64 | All | 94.9 (86.4 to 98.1) | 92.8 (87.7 to 95.7) |